Evidence map›Paper›PMID 35692737›Full record

ArticleBiosensors & bioelectronics: X2022

Improving immunoassay detection accuracy of anti-SARS-CoV-2 antibodies through dual modality validation.

Yuhao Ma, Daniel To, Jie Zeng, Lian C T Shoute, Meng Wu, Shawn Babiuk, Ran Zhuo, Carmen Charlton, Jamil N Kanji, Lorne Babiuk and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors & bioelectronics: X, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuhao MaDepartment of Electrical and Computer Engineering, University of Alberta, Edmonton, AB, T6G 2V4, Canada.
Daniel ToDepartment of Electrical and Computer Engineering, University of Alberta, Edmonton, AB, T6G 2V4, Canada.
Jie ZengDepartment of Electrical and Computer Engineering, University of Alberta, Edmonton, AB, T6G 2V4, Canada.
Lian C T ShouteDepartment of Electrical and Computer Engineering, University of Alberta, Edmonton, AB, T6G 2V4, Canada.
Meng WuDepartment of Chemical and Materials Engineering, University of Alberta, Edmonton, AB, T6G 2R3, Canada.
Shawn BabiukNational Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, MB, Canada.
Ran ZhuoPublic Health Laboratory, Alberta Precision Laboratories, Calgary, AB, Canada.
Carmen CharltonDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, T6G 2B7, Canada.
Jamil N KanjiDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, T6G 2B7, Canada.
Lorne BabiukVaccine and Infectious Disease Organization, University of Alberta, Edmonton, AB, Canada.
Jie ChenDepartment of Electrical and Computer Engineering, University of Alberta, Edmonton, AB, T6G 2V4, Canada.
University of Alberta · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel test strategy is proposed with dual-modality detection techniques for COVID-19 antibody detection. The full-length S protein of SARS-CoV-2 was chemically immobilized on a glass surface to capture anti-SARS-CoV-2 IgG in patient serum and was detected through either Electrochemical Impedance Spectroscopy (EIS) or fluorescence imaging with labeled secondary antibodies. Gold nanoparticles conjugated with protein G were used as the probe and the bound GNP-G was detected through EIS measurements. Anti-human-IgG conjugated with the fluorescent tag Alexa Fluor 488 was used as the probe for fluorescence imaging. Clinical SARS-CoV-2 IgG positive serum and negative controls were used to validate both modalities. For fluorescence-based detection, a high sensitivity was noticed with a quantification range of 0.01-0.1 A.U.C. and a LOD of 0.004 A.U.C. This study demonstrates the possibility of utilizing different measurement techniques in conjunction for improved COVID-19 serology testing.

Indexed as

Anti-SARS-CoV-2 IgGCOVID-19Electrochemical impedance spectroscopy (EIS)Fluorescence labelingSerology testing

Identifiers

PMID35692737
PMCPMC9167148
OpenAlexW4282028400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.